Lyra Therapeutics Inc LYRA

Healthcare Biotechnology

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.

NDAQ:LYRA - Post by User

Lyra Therapeutics Inc

Bullboard Posts

Next >>

Post by whytestockson May 06, 2024 5:15pm

42 Views

Post# 36025804

Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views | Benz

JUST IN: $LYRA Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views | BenzingaU.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday.The Dow traded up 0.25% to 38,772.28 whil...LYRA - Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views | Benzinga

Bullboard Posts

Next >>

A potential breakthrough in spinal cord and optic nerve injury treatment